TuHURA Biosciences, Inc. (HURA): R&D Expense
$20.53M
Year ended 2025-12-31
$22.88M
Trailing 12 months to 2026-06-30
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $20.53M | +54.0% | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | $13.34M | +41.8% | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | $9.40M | n/a | 2025-03-31, From 2023-01-01 |
| No annual figure between 2022-06-30 and 2023-12-31. | |||
| 2022-06-30 | $15.17M | +28.4% | 2023-09-18, From 2021-07-01 |
| 2021-06-30 | $11.81M | +225.5% | 2022-09-27, From 2020-07-01 |
| 2020-06-30 | $3.63M | -0.9% | 2021-09-28, From 2019-07-01 |
| 2019-06-30 | $3.66M | n/c | 2020-09-18, From 2018-07-01 |
| 2018-06-30 | -$7.13M | n/m | 2019-09-09, From 2017-07-01 |
| 2017-06-30 | -$5.00M | n/c | 2018-09-24, From 2016-07-01 |
| 2016-06-30 | $3.36M | +31.5% | 2017-09-27, From 2015-07-01 |
| 2015-06-30 | $2.56M | n/c | 2016-09-13, From 2014-07-01 |
| 2014-06-30 | -$2.12M | n/a | 2015-11-16, From 2013-07-01 |
| No annual figure between 2012-12-31 and 2014-06-30. | |||
| 2012-12-31 | $1.55M | +47.5% | 2014-08-28, From 2012-01-01 |
| 2011-12-31 | $1.05M | n/a | 2014-03-10, From 2011-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| TuHURA Biosciences, Inc. (HURA) | 2025-12-31 | $20.53M | +54.0% |
| Abbott Laboratories (ABT) | 2025-12-31 | $2.94B | +3.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $9.95B | -10.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $13.34B | +21.3% |
| Pfizer Inc (PFE) | 2025-12-31 | $10.44B | -3.6% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $14.66B | -14.9% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $1.90M | +11.8% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $15.79B | -12.0% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $1.90M | -7.5% |
Compare HURA, ABT, BMY, LLY side by side · Screen every company in Pharmaceutical Preparations ↗